Key Therapeutic Agents for Thymic Carcinoma in Real-world Clinical Practice.

IF 1.6 4区 医学 Q4 ONCOLOGY
Akiko Tateishi, Yusuke Okuma, Yasushi Goto, Motoko Arakaki, Yukiko Shimoda Igawa, Masahiro Torasawa, Yuki Shinno, Tatsuya Yoshida, Hidehito Horinouchi, Noboru Yamamoto, Yuichiro Ohe
{"title":"Key Therapeutic Agents for Thymic Carcinoma in Real-world Clinical Practice.","authors":"Akiko Tateishi, Yusuke Okuma, Yasushi Goto, Motoko Arakaki, Yukiko Shimoda Igawa, Masahiro Torasawa, Yuki Shinno, Tatsuya Yoshida, Hidehito Horinouchi, Noboru Yamamoto, Yuichiro Ohe","doi":"10.21873/anticanres.17376","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>Thymic carcinoma is a rare cancer with poor prognosis in unresectable cases. Treatment efficacy of carboplatin+paclitaxel (CP), lenvatinib, S-1, and sunitinib remains uncertain, with some patients experiencing increased post-treatment liver metastasis.</p><p><strong>Patients and methods: </strong>We performed a retrospective analysis of patients with metastatic thymic carcinoma who received chemotherapy between 2006 and 2023 at the National Cancer Center Hospital. We evaluated the clinical outcomes [progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), liver metastasis response rate (LMRR), and liver metastasis control rate (LMCR)] of CP, lenvatinib, S-1, and sunitinib.</p><p><strong>Results: </strong>A total of 178 patients were evaluated, with 78.1% having stage IV disease. Most patients had squamous cell carcinoma (85.4%), and 39 patients had liver metastases (21.9%). The most frequently administered treatments as 1<sup>st</sup>-, 2<sup>nd</sup>-, and 3<sup>rd-</sup> line were CP (85.5%), S-1 (58.3%), and sunitinib (28.4%). The median PFS was 6.8, 9.4, 4.5, and 3.4 months in CP, lenvatinib, S-1, and sunitinib. CP showed an ORR of 41.6% and LMRR of 40.9%. The reverse response, in which only liver metastasis increased despite shrinkage of other lesions, was observed in lenvatinib (20%), S-1 (3.4%), and sunitinib (8.3%).</p><p><strong>Conclusion: </strong>CP and lenvatinib provided effective outcomes in metastatic thymic carcinoma, aligning with previous findings. S-1 and sunitinib also show clinical activity but with variable responses in liver metastases. These results highlight the importance of tailored treatment strategies, particularly for patients with liver involvement.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5501-5513"},"PeriodicalIF":1.6000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17376","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background/aim: Thymic carcinoma is a rare cancer with poor prognosis in unresectable cases. Treatment efficacy of carboplatin+paclitaxel (CP), lenvatinib, S-1, and sunitinib remains uncertain, with some patients experiencing increased post-treatment liver metastasis.

Patients and methods: We performed a retrospective analysis of patients with metastatic thymic carcinoma who received chemotherapy between 2006 and 2023 at the National Cancer Center Hospital. We evaluated the clinical outcomes [progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), liver metastasis response rate (LMRR), and liver metastasis control rate (LMCR)] of CP, lenvatinib, S-1, and sunitinib.

Results: A total of 178 patients were evaluated, with 78.1% having stage IV disease. Most patients had squamous cell carcinoma (85.4%), and 39 patients had liver metastases (21.9%). The most frequently administered treatments as 1st-, 2nd-, and 3rd- line were CP (85.5%), S-1 (58.3%), and sunitinib (28.4%). The median PFS was 6.8, 9.4, 4.5, and 3.4 months in CP, lenvatinib, S-1, and sunitinib. CP showed an ORR of 41.6% and LMRR of 40.9%. The reverse response, in which only liver metastasis increased despite shrinkage of other lesions, was observed in lenvatinib (20%), S-1 (3.4%), and sunitinib (8.3%).

Conclusion: CP and lenvatinib provided effective outcomes in metastatic thymic carcinoma, aligning with previous findings. S-1 and sunitinib also show clinical activity but with variable responses in liver metastases. These results highlight the importance of tailored treatment strategies, particularly for patients with liver involvement.

现实世界临床实践中胸腺癌的关键治疗药物。
背景/目的:胸腺癌是一种罕见的肿瘤,在不能切除的病例中预后较差。卡铂+紫杉醇(CP)、lenvatinib、S-1和舒尼替尼的治疗效果仍不确定,一些患者在治疗后出现肝转移增加。患者和方法:我们对2006年至2023年间在国家癌症中心医院接受化疗的转移性胸腺癌患者进行了回顾性分析。我们评估了CP、lenvatinib、S-1和舒尼替尼的临床结局[无进展生存期(PFS)、客观缓解率(ORR)、疾病控制率(DCR)、肝转移缓解率(LMRR)和肝转移控制率(LMCR)]。结果:共有178例患者被评估,其中78.1%为IV期疾病。大多数患者为鳞状细胞癌(85.4%),39例患者有肝转移(21.9%)。最常用的一线、二线和三线治疗是CP(85.5%)、S-1(58.3%)和舒尼替尼(28.4%)。CP、lenvatinib、S-1和舒尼替尼的中位PFS分别为6.8、9.4、4.5和3.4个月。CP的ORR为41.6%,LMRR为40.9%。lenvatinib组(20%)、S-1组(3.4%)和舒尼替尼组(8.3%)的相反反应是,尽管其他病变缩小,但只有肝转移增加。结论:CP联合lenvatinib治疗转移性胸腺癌疗效显著,与之前的研究结果一致。S-1和舒尼替尼也表现出临床活性,但对肝转移的反应不同。这些结果强调了定制治疗策略的重要性,特别是对于肝脏受累的患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Anticancer research
Anticancer research 医学-肿瘤学
CiteScore
3.70
自引率
10.00%
发文量
566
审稿时长
2 months
期刊介绍: ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信